Kasarki 32 mg is used for the treatment of primary arterial hypertension in adults and in children and adolescents aged 6 to 18 years.
Active ingredient: Candesartan cilexetil;
Each tablet contains candesartan cilexetil equivalent to 32 mg of the active substance.
Excipients: Calcium carmellose; corn starch; hydroxypropyl cellulose; lactose monohydrate; magnesium stearate; polyethylene glycol (PEG 8000).
Treatment of primary arterial hypertension in adults;
Treatment of arterial hypertension in children and adolescents aged 6 to 18 years;
Treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction ≤ 40%), as an adjunct therapy with ACE inhibitors or in cases of ACE inhibitor intolerance.
Hypersensitivity to candesartan cilexetil or any excipients;
Severe liver dysfunction and/or cholestasis;
Use during the second or third trimester of pregnancy;
Children under 1 year old;
Concurrent use with ACE inhibitors or angiotensin II receptor antagonists-containing aliskiren is contraindicated in patients with diabetes mellitus or impaired renal function (GFR < 60 ml/min/1.73 m²).
Arterial Hypertension
The recommended initial and maintenance dose of Kasarki is 8 mg once daily. The main antihypertensive effect is achieved within 4 weeks of treatment initiation. If blood pressure is not adequately controlled, the dose can be increased to 16 mg once daily, and up to a maximum of 32 mg once daily. Treatment should be adjusted based on blood pressure response.
Renal Impairment
For patients with renal impairment, including those on hemodialysis, the starting dose is 4 mg once daily. The dose should be titrated according to clinical response. Limited experience exists for use in patients with severe renal impairment or renal failure (creatinine clearance < 15 ml/min).
Liver Impairment
An initial dose of 4 mg once daily is recommended for patients with mild to moderate liver impairment. Dose adjustment should be based on clinical response. Kasarki is contraindicated in patients with severe liver failure and/or cholestasis.
Children and Adolescents Aged 6 to 18 Years
The recommended initial dose is 4 mg once daily.
For patients weighing less than 50 kg: if blood pressure is inadequately controlled, the dose may be increased up to a maximum of 8 mg once daily.
For patients weighing 50 kg or more: if blood pressure is inadequately controlled, the dose may be increased to 8 mg once daily and, if necessary, up to 16 mg once daily.
Store in the original packaging at temperatures not exceeding 25°C. Keep out of reach of children.
